Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals
What Tatva files
- Investor Meet54
- Others52
- Important15
- PPTs8
- Board Meeting8
- Dividend/Bonus4
Tatva Chintan Pharma Chem (TCPCL) delivered strong Q1 FY27 results. Revenue from operations jumped 43% year-over-year (YoY) to ₹167.1 Cr. Profit After Tax (PAT) surged 140% YoY to ₹16 Cr, with EBITDA growing 86% YoY to ₹32.3 Cr. Key revenue drivers included Pharma & Agrochemical Intermediates (PASC) at 35%, Structure...
Tatva Chintan Pharma Chem delivered strong performance for the latest quarter and full fiscal year. Full-year revenue from operations increased 32% to ₹505.9 Cr, with profit after tax (PAT) surging 636% to ₹42.1 Cr. For the latest quarter, revenue grew 24% to ₹134.1 Cr, and PAT soared 902% to ₹10.3...
Tatva Chintan Pharma Chem reported strong Q3 FY26 financial results. Revenue from operations soared to 131.3 Cr, a 53% increase year-on-year. Profit after tax (PAT) saw a significant jump to 15.2 Cr, marking a remarkable 10,889% YoY growth, with Earnings Per Share (EPS) at ₹6.49. For the nine months ending...
Tatva Chintan Pharma Chem delivered robust consolidated Q2 FY26 results. Revenue surged 48% year-on-year to ₹123.5 Cr, with Profit After Tax (PAT) dramatically increasing to ₹9.9 Cr from a previous loss. For H1 FY26, revenue grew 27% year-on-year to ₹240.4 Cr, and PAT climbed 265% to ₹16.6 Cr. Earnings per...
**1. Financial Highlights:** Q1 FY26 saw revenue up 11% YoY to ₹116.9 Cr. EBITDA jumped 37% to ₹17.3 Cr (14.8% margin), and PAT grew 28% to ₹6.7 Cr (5.7% margin). While FY25 revenue slightly dipped and PAT dropped significantly, the balance sheet indicates low net debt. **2. Strategic Initiatives &...